MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/cpdd.1569

Медицинская библиотека · Clinical pharmacology in drug development · 2025

A Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-101, an RNAi Therapeutic Targeting HBV Infection.

Zhang Jianxiong, Li Jiangshuo, Wu Le, Song Yuqin, Li Xiao, Gao Qiannan, Wu Jingxuan, Wang Dong, Zhang Zhipeng, Zhang Shanzhong, Ding Lijuan, Ma Yanqin, Ma Hong, Jia Jidong, Dong Ruihua

СтатьяРандомизированное исследованиеКлиническое исследование I фазыПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

HT-101, a liver-targeted N-acetylgalactosamine-conjugated ribonucleic acid interference therapeutic, exhibits promising potential for the treatment of chronic hepatitis B virus infection. This randomized, double-blind, placebo-controlled, and single-ascending-dose Phase Ia study included 50 healthy volunteers. Regarding methods, 2 subjects received a single subcutaneous dose of HT-101 at 25 mg, while 48 volunteers were randomized (6:2 active:placebo) in the remaining 6 cohorts to receive a single subcutaneous dose of HT-101 (50-800 mg) or placebo. Afterward, serial blood samples were obtained for pharmacokinetic determination across a 48-hour postdose period. Safety assessments included clinical laboratory measures, vital signs, and 12-lead electrocardiogram before and after dosing. As a result, plasma pharmacokinetics characterized by functional antisense strand revealed a median time to peak plasma concentration of 2.5-6.0 hours, and a short median plasma half-life of 2.50-6.14 hours. It is underlined that peak and total plasma exposure to HT-101 increased in a slightly greater-than-dose-proportional manner following 25-800 mg administered subcutaneously. Moreover, a single dose of HT-101 at 25-800 mg was safe and well tolerated in healthy Chinese volunteers. These data can support further clinical development of HT-101 for hepatitis B virus infection treatment.

Для цитирования: Zhang Jianxiong, Li Jiangshuo, Wu Le, Song Yuqin, Li Xiao, Gao Qiannan, Wu Jingxuan, Wang Dong, Zhang Zhipeng, Zhang Shanzhong, Ding Lijuan, Ma Yanqin, Ma Hong, Jia Jidong, Dong Ruihua. A Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-101, an RNAi Therapeutic Targeting HBV Infection.. Clinical pharmacology in drug development. 2025. DOI: 10.1002/cpdd.1569.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.